CD274 and neoplasm: The rationale for employing immunotherapy in CC is strongly supported by multiple molecular features, such as high tumor mutational burden (TMB), microsatellite instability (MSI), high expression of programmed death ligand 1 (PD-L1) and high tumor inflammatory state.